The Invitae Breast Cancer Panel analyzes genes that are associated with hereditary breast cancer. The primary panel includes 14 genes associated with hereditary breast cancer. In addition to the primary panel, clinicians can also choose to include 14 genes that have preliminary evidence of an association with breast cancer. At this time, the association of these genes with breast cancer remains uncertain; however, some clinicians may wish to include genes that may prove to be clinically significant in the future.
A study looking at testing all Ashkenazi Jewish people for a cancer gene (GCaPPS)
The Breast Cancer Genes
They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double-strand breaks. The predominant allele has a normal, tumor suppressive function whereas high penetrance mutations in these genes cause a loss of tumor suppressive function which correlates with an increased risk of breast cancer. Thus, this protein plays a role in transcription, and DNA repair of double-strand DNA breaks  ubiquitination , transcriptional regulation as well as other functions. Myriad Genetics lawsuit.
BRCA Gene Mutations: Cancer Risk and Genetic Testing
Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast—ovarian cancer syndrome in affected persons. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive sentinel lymph node s SLN[s] after completion of neoadjuvant chemotherapy. To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of the incidence of invasive loco-regional recurrences in patients with a positive SLN s after completion of neoadjuvant chemotherapy. To obtain an estimate of the distribution of residual disease burden scores.